Stefan Rehnmark
Direttore Tecnico/Scientifico/R&S presso GABATHER AB
Profilo
Stefan Rehnmark is the founder of Axcentua Pharmaceuticals AB, which was founded in 2007.
He held the title of Chief Executive & Scientific Officer at the company.
Dr. Rehnmark is also the founder of Noviga Research AB.
He is currently the Chief Scientific Officer at Gabather AB.
Dr. Rehnmark previously worked as an Assistant Professor at the University of Stockholm from 1994 to 2000.
He obtained a doctorate degree from the University of Stockholm.
Posizioni attive di Stefan Rehnmark
Società | Posizione | Inizio |
---|---|---|
GABATHER AB | Direttore Tecnico/Scientifico/R&S | 01/01/2018 |
Precedenti posizioni note di Stefan Rehnmark
Società | Posizione | Fine |
---|---|---|
University of Stockholm | Corporate Officer/Principal | 01/01/1998 |
Noviga Research AB | Fondatore | - |
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Amministratore Delegato | - |
Formazione di Stefan Rehnmark
University of Stockholm | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GABATHER AB | Health Technology |
Aziende private | 2 |
---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
Noviga Research AB |
- Borsa valori
- Insiders
- Stefan Rehnmark